Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

80.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
80.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

14.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.2K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AhR inhibition promotes axon regeneration via a stress-growth switch.

Nature·2026
Same author

Novel Neurotrophin-3 peptidomimetic synthetic neurotrophin promotes neurological recovery after spinal cord injury.

Experimental neurology·2026
Same author

PROTACs for Collateral Degradation: Is It Time to Back Up the Bus?

ACS medicinal chemistry letters·2026
Same author

Forces behind N- and C-capping of peptidic helices.

Chemical communications (Cambridge, England)·2026
Same author

Cancer immunotherapeutic targeting tropomyosin receptor kinase C (TrkC) through its conjugate and cyclophosphamide.

Immunopharmacology and immunotoxicology·2025
Same author

SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice.

Journal of neurotrauma·2025
Same journal

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same journal

Charting New Territory: Systematic Evaluation of the Drug Potential of <i>N</i>-Trifluoromethyl Amides, Ureas & Carbamates.

Journal of medicinal chemistry·2026
Same journal

Red-Light-Triggered <i>In Vitro</i> and <i>In Vivo</i> Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts.

Journal of medicinal chemistry·2026
Same journal

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same journal

HsClpP-Engaging Selective Mitochondrial Pan-PDK Degraders for Cancer Therapy.

Journal of medicinal chemistry·2026
Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Sep 15, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.6K

Small-Molecule Trk Agonists: Where Do We Go from Here?

Tye S Thompson1, Arthur Sefiani2, Kevin Burgess1

  • 1Department of Chemistry, Texas A&M University, Box 30012, College Station, Texas 77842-3012, United States.

Journal of Medicinal Chemistry
|July 18, 2025
PubMed
Summary
This summary is machine-generated.

Researchers explored small-molecule modulators for Trk (tropomyosin receptor kinase) to treat neurodegeneration and injuries. Prioritizing existing drugs in screening accelerated discovery but faced constraints, impacting current development.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.2K

Related Experiment Videos

Last Updated: Sep 15, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.6K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Trk (tropomyosin receptor kinase) modulators were absent two decades ago.
  • Trk's potential in neurodegeneration and traumatic injuries spurred research.
  • High-throughput screening (HTS) offered a path to identify modulators.

Purpose of the Study:

  • To review the historical efforts in identifying Trk modulators via HTS.
  • To discuss lessons learned from past drug discovery strategies.
  • To identify current constraints hindering Trk modulator development.

Main Methods:

  • Review of past high-throughput screening campaigns for Trk modulators.
  • Analysis of filtering criteria, including prioritization of existing pharmaceuticals.
  • Examination of cost and effort constraints in library screening.

Main Results:

  • HTS of commercial libraries identified potential Trk modulators.
  • Prioritizing existing drugs offered known safety and BBB permeability data.
  • Screening limitations due to cost and effort impacted compound numbers.

Conclusions:

  • Past HTS efforts provided valuable insights into Trk modulator discovery.
  • Lessons learned highlight the importance of strategic library filtering.
  • Current development is constrained by factors identified in this review.